Related Experiment Video
Updated: Apr 2, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Systemic therapy for metastatic extramammary Paget's disease
Chunxia Zhao1,2,3,4, Hang Li1,2,3,4
1Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
None:
Extramammary Paget's disease is a rare cutaneous malignancy. Although most patients exhibit a favorable prognosis, those with metastatic extramammary Paget's disease typically face poor outcomes, necessitating effective therapeutic strategies to improve survival and disease management. Due to the rarity of this condition, no standardized treatment consensus exists for the disease. In this review, we summarize current treatment modalities for metastatic extramammary Paget's disease, including chemotherapy, hormonal therapy, targeted therapy, immune checkpoint inhibition, and several emerging novel therapies, which demonstrate variable disease control rates and survival outcomes. Additionally, we explore the potential of promising therapeutic approaches for future applications. Further large-scale clinical studies and well-designed therapeutic trials are required to establish optimal treatment regimens.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

